Top German Pharma Boehringer Wins US Approval for Cancer Drug

Top German pharma Boehringer wins US approval for cancer drug

Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company.

Top German Pharma Boehringer Wins US Approval for Cancer Drug

Boehringer Ingelheim GmbH won approval in the US for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company.

US FDA approves Boehringer Ingelheim’s lung cancer treatment - Regional Media News

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved Boehringer Ingelheim’s drug for patients with a type of advanced lung cancer who have received prior treatment. The drug, branded as Hernexeos, is intended for previously treated patients with non-squamous non-small cell lung cancer whose tumors have a specific genetic mutation. The regulator’s approval was based on a study in which Hernexeos helped about 75% of pati…

FDA Approves Hernexeos for Non-Squamous Non-Small Cell Lung Cancer

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.